Atlas Trials

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

Clinical trial NCT06920199 · RECRUITING

Trial details

NCT number
NCT06920199
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
cGVHD
Start date
2025-06-14
Primary completion
2027-05-15
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.